Stockscreener 앱 받기
2.16
4.35%
0.09
전일 마감가:
$2.07
열려 있는:
$2.06
하루 거래량:
397.77K
Relative Volume:
1.48
시가총액:
$45.44M
수익:
-
순이익/손실:
$-7.79M
주가수익비율:
-4.4981
EPS:
-0.4802
순현금흐름:
$-8.94M
1주 성능:
+1.41%
1개월 성능:
-12.20%
6개월 성능:
-40.17%
1년 성능:
-29.87%
1일 변동 폭
$2.02
$2.19
1주일 범위
$2.02
$2.19
52주 변동 폭
$1.79
$5.18
Grace Therapeutics Inc Stock (GRCE) Company Profile
명칭
Grace Therapeutics Inc
전화
609-322-1602
주소
103 CARNEGIE CENTER, PRINCETON
Compare GRCE vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GRCE
Grace Therapeutics Inc
|
2.16 | 44.18M | 0 | -7.79M | -8.94M | -0.4802 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Grace Therapeutics Inc Stock (GRCE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-02 | 개시 | TD Cowen | Buy |
| 2020-09-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-07-06 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2020-01-13 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2019-08-29 | 개시 | B. Riley FBR | Buy |
| 2019-07-18 | 개시 | Oppenheimer | Outperform |
| 2019-06-26 | 개시 | H.C. Wainwright | Buy |
모두보기
Grace Therapeutics Inc 주식(GRCE)의 최신 뉴스
Grace Therapeutics (GRCE): ADAR1 group discloses 9.9% beneficial stake via warrants - Stock Titan
Grace Therapeutics (GRCE) investor group reports 6.75% stake via convertibles - Stock Titan
Grace Therapeutics, Inc. Reports Impairment charges for the First Quarter Ended June 30, 2026 - marketscreener.com
Grace Therapeutics, Inc. (NASDAQ: GRCE) Share Price, GRCE Stock News, GRCE Share Price & Updates - Kalkine
Grace Therapeutics Q1 Results: EPS Misses Estimate, Losses Widen - scanx.trade
Form 8K Grace Therapeutics, Inc For: 13 August By Investing.com - Investing.com Nigeria
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update - The Manila Times
Grace Therapeutics Reports $15.8 Million First-Quarter Net Loss - Quiver Quantitative
Grace Therapeutics, Inc. Q1 2027: Net loss $(15.8)M, EPS $(0.91) — 10-Q Summary - TradingView
Grace Therapeutics (GRCE) books $13.5M R&D impairment, extends cash runway to 2028 - Stock Titan
Grace Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026 - marketscreener.com
Grace Therapeutics (GRCE) completes $9.99M Rule 506(b) private equity raise - Stock Titan
GRCE Stock On Track For Worst Week In 5.5 Years — What’s Driving The Selloff? - Stocktwits
Grace Therapeutics (GRCE): Opaleye reports 2.75M-share, 13.07% ownership stake - Stock Titan
Grace Therapeutics, Inc. Revenue Breakdown – NASDAQ:GRCE - TradingView
Grace Therapeutics Raises Capital to Advance GTx-104 Program - TipRanks
Grace Therapeutics Raises $10 Million in Private Placement, Grants Registration Rights - TradingView
Grace Therapeutics announces securities purchase agreement for $10M private placement - ROI-NJ
Grace Therapeutics (GRCE) Raises $10M in Private Placement Amid High Price-to-Sales Valuation - GuruFocus
GRCE Q1'26 Earnings: EPS estimate is (0.13) USD - TradingView
Grace Therapeutics Secures $10M Private Placement Agreement - Intellectia AI
Grace Therapeutics, Inc. announced that it has received $9.999998 million in funding - marketscreener.com
Grace Therapeutics Expects Funding to Extend Cash Runway Through 2028 - Stock Titan
Grace Therapeutics raises $10 million in private placement By Investing.com - Investing.com Australia
Grace Therapeutics raises $10 million in private placement - Investing.com
Grace Therapeutics raises $10M in private place... - pluang.com
Grace Therapeutics Announces $10 Million Private Placement Financing to Support GTx-104 Development - quiverquant.com
Grace Therapeutics Announces $10 Million Private Placement - Moomoo
Grace Therapeutics prices USD 10 million private placement at USD 2.1 per share - Bitget
Grace Therapeutics, Inc. announced that it expects to receive $9.999998 million in funding - marketscreener.com
GRCE Q1'26 Earnings: revenue estimate is 0 USD - TradingView
Grace Therapeutics Receives Type a Meeting Minutes from FDA and Provides Update on GTx-104 Clinical-Stage Injectable Formulation - marketscreener.com
Grace Therapeutics (GRCE) FDA Meeting Highlights Manufacturing Compliance Focus, Market Implies High Growth - GuruFocus
Grace Therapeutics receives FDA meeting minutes on GTx-104 - Investing.com
Grace Therapeutics advances dual-source manufacturing for GTx-104 - TipRanks
Grace receives FDA Type A meeting minutes; advances dual-source manufacturing toward NDA resubmission - TradingView
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration - The Manila Times
Grace Therapeutics receives FDA meeting minutes on GTx-104 By Investing.com - Investing.com Canada
Grace Therapeutics Says FDA Minutes Confirm No Clinical Safety or Efficacy Deficiencies in GTx-104 Review, Advances Dual-Source Manufacturing Plan Toward NDA Resubmission - Quiver Quantitative
Grace Therapeutics Advances Second U.S. Manufacturing Route for GTx-104 - Stock Titan
Grace Therapeutics, Inc (GRCE) Institutional Confidence - TradingKey
GRCE Stock On Retail Watchlist: High-Stakes FDA Decision On Brain Bleed Drug Nears - Stocktwits
Grace Therapeutics, Inc (GRCE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Grace Therapeutics, Inc (GRCE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Grace Therapeutics, Inc (GRCE) Cash Flow - TradingKey
Price to sales forward of Grace Therapeutics, Inc. – FWB:L8S - TradingView
GRCE|Grace Therapeutics, Inc|Price:2.330|Chg%:-0.020 - TradingKey
Price to earnings forward of Grace Therapeutics, Inc. – FWB:L8S - TradingView
Grace Therapeutics Inc. (GRCE) Q2 2026 Earnings: Significant EPS Beat Driven by Cost DisciplineROIC Trend Report - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therape - The National Law Review
Craig-Hallum Maintains Grace Therapeutics(GRCE.US) With Buy Rating - Moomoo
Grace Therapeutics Inc (GRCE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):